ReviewTranslational lung cancer research2015
Epidermal growth factor receptor in non-small cell lung cancer.
Review in Translational lung cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 95 citations in OpenAlex.
- Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.Targeted oncology · 2023Trial
- Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.Cancer science · 2019Trial
- Unveiling BRAF Mutations in Non-small Cell Lung Cancer: State of the Art and Future Perspectives.Lung · 2026Review
- Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics.Nuklearmedizin. Nuclear medicine · 2026Article
- Extracellular Vesicles in Cancer Diagnosis and Therapy: Advances, Challenges, and Prospects for Clinical Translation.International journal of molecular sciences · 2026Review
- Buddlejasaponin IV inhibits proliferation and migration via STAT3 suppression in gefitinib-resistant non-small cell lung cancer cells.BMC complementary medicine and therapies · 2026Article
- Exosomal biomarkers and therapeutics in lung cancer: a narrative review on their role in early detection and targeted treatment.Translational lung cancer research · 2025Review
- Review
- Shared neoantigens for cancer immunotherapy.Molecular therapy. Oncology · 2025Review
- Radiocobalt theranostic applications: current landscape, challenges, and future directions.Frontiers in nuclear medicine · 2025Review
- Review of Plasma Exosomal DNA for Detecting EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).Advanced biomedical research · 2025Review
- Advancing precision oncology with AI-powered genomic analysis.Frontiers in pharmacology · 2025Review
- Analysis of the Relationship Between EGFR Mutations and PD-L1, ALK, and ROS1 Alterations in Patients with Non- Small-Cell Lung Cancer: The Most Extensive Study Conducted in Iran.Turk patoloji dergisi · 2025Article
- Immuno-PET Imaging of EGFR withMolecular pharmaceutics · 2024Article
- Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents.Cell communication and signaling : CCS · 2024Review
- Lung cancer cell-derived exosomes: progress on pivotal role and its application in diagnostic and therapeutic potential.Frontiers in oncology · 2024Review
- Predicting drug response from single-cell expression profiles of tumours.BMC medicine · 2023Article
- α-Viniferin-Induced Apoptosis through Downregulation of SIRT1 in Non-Small Cell Lung Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model.Acta pharmacologica Sinica · 2022Article
- Antiproliferative Activity of a New Quinazolin-4(3Pharmaceuticals (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following the identification of a group of patients in the initial tyrosine kinase inhibitor (TKI) trials for lung cancer, there has been detailed focus on which patients may benefit from inhibitor therapy. This article reviews the background, genetics and prevalence of epidermal growth factor mutations in non-small cell lung cancer (NSCLC). Additionally, the prevalence in unselected patients is compared against various other reviews.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.